Sep 13, 2022 6:45 am EDT Kiora Pharmaceuticals Appoints Melissa Tosca as Executive Vice President of Finance
Aug 12, 2022 6:45 am EDT Kiora Pharmaceuticals Reports First Half 2022 Business Update and Financial Results
Aug 9, 2022 11:00 am EDT Kiora Pharmaceuticals To Participate in the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference; Online Presentation Will Be Available August 17, 2022 at 7:00 am EST
Jul 28, 2022 6:45 am EDT Kiora Pharmaceuticals Issued US Patent Covering KIO-201 Technology in Combination with Antibiotics
Jul 26, 2022 4:38 pm EDT Kiora Pharmaceuticals Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option
Jul 22, 2022 8:30 am EDT Kiora Pharmaceuticals Announces Pricing of $5.2 Million Underwritten Public Offering
Jul 5, 2022 6:45 am EDT Kiora Pharmaceuticals Announces First Patient Enrolled in Phase 2 Study Evaluating KIO-201 for Persistent Corneal Epithelial Defects
Jun 27, 2022 6:53 am EDT Kiora Pharmaceuticals Receives Clinical Trial Approval for First-in-Human Evaluation of KIO-301 to Restore Vision in Patients with Retinitis Pigmentosa
May 31, 2022 4:30 pm EDT Kiora Pharmaceuticals Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1)